Scholars Central

Conference abstractPublished 2015

Perspective on Challenges Facing Injectable Products

Authors: Diane Paskiet

West Pharmaceutical Services, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The outlook for sterile injectable products continues to expand as do the many challenges facing pharmaceutical manufactures. Research and development efforts are now focused on patient centric therapies and the quality of medicines will be judged accordingly. Influencing factors include the drive to lower medical costs by enabling at-home self administration and promoting adherence with delivery devices designed to meet patient needs. In addition, approvals of biologics are on the rise and being facilitated by FDA expedited approval pathways for novel drugs. The injectable route of administration is common to many biologics which contributes to the increased need for qualified delivery system. A key consideration during drug product development is the interaction between multiple components that will collectively affect performance and quality of the final product. Building quality into drug products also includes efficient manufacturing capabilities. The lack of scientific understanding and inadequate manufacturing controls has led to shortages according to FDA. Combined challenges are linked to qualifying components, processing and filling, complex supply chains, and evolving globalization. These variables can generate an abundance of risked factors which can result in long development times, product recalls, and shortages of lifesaving medicines. Risk management and quality by design (QbD) paradigms have become the standard approach for drug development but the fact remains that therapies can only be effective if the medicine can be successfully delivered to the patient. Integral to the drug product are the protection of medicines and safe delivery to the patient, which are essential elements for achieving positive outcomes. The progression of the QbD paradigm should bring together drug development and manufacture with containment and delivery systems. These concepts can be applicable to the final drug product and its critical material attributes, such as components of delivery systems. A comprehensive science based program for product and process understanding will allow efficient manufacture of quality products to be safely delivered to the patient.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutics & Drug Delivery Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutics & Drug Delivery Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Diane Paskiet”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels